Literature DB >> 19222674

An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial.

Daniel M Riche1, Deborah S Minor, Amber S Holdiness, Honey E East.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19222674      PMCID： PMC8673153          DOI： 10.1111/j.1751-7176.2008.00069.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  13 in total

1.  Standards of medical care in diabetes--2008.

Authors: 
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

2.  Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

Authors:  P Svensson; U de Faire; P Sleight; S Yusuf; J Ostergren
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

3.  The COOPERATE trial: a letter of concern.

Authors:  Regina Kunz; Marcel Wolbers; Tracy Glass; Johannes F E Mann
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

4.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

6.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

7.  Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.

Authors:  D L Jennings; J S Kalus; C I Coleman; C Manierski; J Yee
Journal:  Diabet Med       Date:  2007-03-15       Impact factor: 4.359

8.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

9.  Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies.

Authors:  David H G Smith; Maarten-Jan M Cramer; Joel M Neutel; Rohan Hettiarachchi; Stephen Koval
Journal:  Blood Press Monit       Date:  2003-06       Impact factor: 1.444

10.  Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats.

Authors:  D J Kelly; Y Zhang; G Moe; G Naik; R E Gilbert
Journal:  Diabetologia       Date:  2007-09-08       Impact factor: 10.122
View more
  4 in total

Review 1.  Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases.

Authors:  Shahid Nadeem; Donald L Batisky
Journal:  Pediatr Nephrol       Date:  2013-12-14       Impact factor: 3.714

Review 2.  Aliskiren and valsartan combination therapy for the management of hypertension.

Authors:  Benjamin J Epstein
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

3.  Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse.

Authors:  Masako Furukawa; Tomohito Gohda; Shinji Hagiwara; Mitsuo Tanimoto; Satoshi Horikoshi; Kazuhiko Funabiki; Yasuhiko Tomino
Journal:  Int J Nephrol       Date:  2013-06-02

4.  Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus.

Authors:  Yutaka Mori; Shizuka Aritomi; Kazumi Niinuma; Tarou Nakamura; Kenichi Matsuura; Junichi Yokoyama; Kazunori Utsunomiya
Journal:  Drug Des Devel Ther       Date:  2014-06-17       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.